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Summary
Background
After breast-conserving surgery, radiotherapy reduces recurrence and breast cancer death, but it may
do so more for some groups of women than for others. We describe the absolute magnitude of these
reductions according to various prognostic and other patient characteristics, and relate the absolute
reduction in 15-year risk of breast cancer death to the absolute reduction in 10-year recurrence risk.
Methods
We undertook a meta-analysis of individual patient data for 10 801 women in 17 randomised trials of
radiotherapy versus no radiotherapy after breast-conserving surgery, 8337 of whom had pathologically
confirmed node-negative (pN0) or node-positive (pN+) disease.
Findings
Overall, radiotherapy reduced the 10-year risk of any (ie, locoregional or distant) first recurrence from
35·0% to 19·3% (absolute reduction 15·7%, 95% CI 13·7–17·7, 2p<0·00001) and reduced the 15-year risk
of breast cancer death from 25·2% to 21·4% (absolute reduction 3·8%, 1·6–6·0, 2p=0·00005). In women
with pN0 disease (n=7287), radiotherapy reduced these risks from 31·0% to 15·6% (absolute recurrence
reduction 15·4%, 13·2–17·6, 2p<0·00001) and from 20·5% to 17·2% (absolute mortality reduction 3·3%,
0·8–5·8, 2p=0·005), respectively. In these women with pN0 disease, the absolute recurrence reduction
varied according to age, grade, oestrogen-receptor status, tamoxifen use, and extent of surgery, and
these characteristics were used to predict large (≥20%), intermediate (10–19%), or lower (<10%)
absolute reductions in the 10-year recurrence risk. Absolute reductions in 15-year risk of breast cancer
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death in these three prediction categories were 7·8% (95% CI 3·1–12·5), 1·1% (–2·0 to 4·2), and 0·1% (–
7·5 to 7·7) respectively (trend in absolute mortality reduction 2p=0·03). In the few women with pN+
disease (n=1050), radiotherapy reduced the 10-year recurrence risk from 63·7% to 42·5% (absolute
reduction 21·2%, 95% CI 14·5–27·9, 2p<0·00001) and the 15-year risk of breast cancer death from
51·3% to 42·8% (absolute reduction 8·5%, 1·8–15·2, 2p=0·01). Overall, about one breast cancer death
was avoided by year 15 for every four recurrences avoided by year 10, and the mortality reduction did
not differ significantly from this overall relationship in any of the three prediction categories for pN0
disease or for pN+ disease.
Interpretation
After breast-conserving surgery, radiotherapy to the conserved breast halves the rate at which the
disease recurs and reduces the breast cancer death rate by about a sixth. These proportional benefits
vary little between different groups of women. By contrast, the absolute benefits from radiotherapy vary
substantially according to the characteristics of the patient and they can be predicted at the time when
treatment decisions need to be made.
Funding
Cancer Research UK, British Heart Foundation, and UK Medical Research Council.
Introduction
For many women with early-stage breast cancer, breast-conserving surgery can remove any
macroscopic disease that has been detected; however, some microscopic tumour foci might remain in
the conserved breast that could, if untreated, lead to locoregional recurrence or life-threatening distant
metastases, or both. This report updates previous analyses from the Early Breast Cancer Trialists'
Collaborative Group (EBCTCG) of individual patient data from the randomised trials of radiotherapy
after breast-conserving surgery.1–5 It includes further follow-up for nine of the ten trials analysed
previously;5 adds data from seven new trials, six of which were in low-risk women; and increases the
total number of women analysed by nearly 50%. The report focuses mainly on women for whom
pathological axillary lymph node status is known (negative [pN0] or positive [pN+]), because such
information is usually available nowadays. It assesses the extent to which the radiotherapy-related
absolute reduction in 10-year risk of first recurrence at any site (locoregional or distant) varies for
women with different prognostic and other factors. It then relates the absolute reduction in the 15-year
risk of breast cancer death to the absolute reduction in the 10-year risk of a recurrence.
Methods
Study design
Eligible trials were those beginning before the year 2000 of adjuvant radiotherapy versus no
radiotherapy following breast-conserving surgery for invasive cancer. Trial identification and data
handling were as previously reported.5 For every woman, information was sought regarding initial
characteristics, allocated treatment, time to first recurrence, whether the first recurrence was
locoregional or distant (excluding contralateral breast cancer), and date last known alive or date and
underlying cause of death. When no recurrence was reported before breast cancer death, distant
recurrence was assumed to have just preceded it. If contralateral breast cancer occurred before any
other recurrence, follow-up was censored on that date in recurrence analyses.
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Statistical analysis
The method used in this study differs from that used previously.5 First, to avoid assumptions about
how locoregional and distant recurrence relate to each other, the main emphasis is on analyses of any
first recurrence rather than, as before, of time to locoregional recurrence as a first event. Second, most
analyses of recurrence present data for only 10 years, because many of these trials did not follow up
women beyond this time for recurrence. This absence of follow-up should not bias the estimated
proportional effect on recurrence after year 10, but could affect estimates of the absolute recurrence risk
after year 10 substantially. Third, deaths of unknown cause before recurrence are no longer attributed
to breast cancer, because most occurred many years after trial entry, by which time non-breast-cancer
mortality predominated. Other aspects of the methods used are as before.5 Log-rank analyses are
stratified by trial, individual follow-up year, and nodal status. They are also stratified by age, either in
five groups (<40, 40–49, 50–59, 60–69, 70+ years) or, when data are also subdivided by other factors,
in two groups (<50 and 50+ years).
Analyses of the dependence of absolute risk, and absolute risk reduction, on several factors
simultaneously use Poisson regression fitted by maximum likelihood (webappendix pp 20–25). In these
analyses absolute risk of any first recurrence is adjusted for trial, individual follow-up year, nodal
status, and age (five groups), and also for tumour grade, tumour size, oestrogen-receptor (ER) status,
and whether or not tamoxifen had been used in both randomised groups in the trial.
Preliminary results were presented to collaborators in September, 2010. A report was circulated to
collaborators for comment in January, 2011, and then revised centrally.
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data
interpretation, or writing of the report. The Secretariat had full access to all data and analyses.
Submission for publication was decided only by the writing committee.
Results
Information was available for 10 801 women in 17 trials (table 1). Six trials were of radiotherapy after
lumpectomy and included both low-risk and high-risk women (category A, 4398 women), four were of
radiotherapy after sector resection or quadrantectomy (category B, 2399 women), and seven more
recent trials were of radiotherapy after lumpectomy in low-risk women (category C, 4004 women). In
most of the trials radiotherapy was to the conserved breast only (webappendix p 4). Median follow-up
was 9·5 years at risk per woman and 25% of women were followed up for more than a decade. 3143
(29%) had died by the final follow-up date of Sept 30, 2006.
The 10-year risk of any (locoregional or distant) first recurrence was 19·3% in women allocated to
radiotherapy and 35·0% in women allocated to breast-conserving surgery only, corresponding to an
absolute risk reduction of 15·7% (95% CI 13·7–17·7, 2p<0·00001; figure 1). Nearly three-quarters of first
recurrences in the no radiotherapy group were locoregional (25% locoregional first, 10% distant first),
compared with fewer than half of those in the radiotherapy group (8% locoregional first, 12% distant
first; webappendix p 9). In addition to reducing recurrence substantially, radiotherapy also reduced
breast cancer death by a moderate amount: the 15-year absolute risk reduction was 3·8% (95% CI 1·6–
6·0, 2p=0·00005), suggesting on average about one breast cancer death avoided for every four
recurrences avoided by radiotherapy.
Allocation to radiotherapy halved the average annual rate of any first recurrence (rate ratio [RR] 0·52,
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95% CI 0·48–0·56, figure 1). The proportional reduction was greatest in the first year (0·31, 0·26–0·37),
but was still substantial during years 5–9 (0·59, 0·50–0·70; webappendix p 13). Beyond year 10 there
was no evidence of any further effect on the first recurrence rate, but information about recurrence in
this period was incomplete so the number of events was small and the CI wide (figure 1). Radiotherapy
reduced the annual breast cancer death rate by a sixth (RR 0·82, 0·75–0·90). The timing of breast
cancer death differed from that of first recurrence, with few events during the first year (figure 1), and
there were substantial numbers of breast cancer deaths after year 10.
Mortality without recurrence from non-breast-cancer causes was slightly higher in women allocated to
radiotherapy than in women allocated to breast-conserving surgery only, but the excess was not
significant (RR 1·09, 95% CI 0·97–1·22, 2p=0·14). If the mortality rate from non-breast-cancer causes
in women allocated to radiotherapy had been identical to that in women allocated to breast-conserving
surgery only, then the 15-year absolute risk reduction in all-cause mortality would have been 3·2%. In
fact, the 15-year absolute risk reduction in all-cause mortality was 3·0% (95% CI 0·6–5·4, 2p=0·03; 
figure 1).
Most women (n=7287) had pN0 disease. In this group, allocation to radiotherapy halved the average
annual recurrence rate during the first decade (RR 0·46, 95% CI 0·41–0·51), reducing the 10-year risk
of any first recurrence from 31·0% to 15·6%, an absolute reduction of 15.4% (95% CI 13·2–17·6,
2p<0.00001 figure 2). For these women, radiotherapy reduced breast cancer death by about a sixth (RR
0·83, 95% CI 0·73–0·95), and reduced the 15-year risk of breast cancer death from 20·5% to 17·2%, an
absolute reduction of 3·3% (95% CI 0·8–5·8, 2p=0.005; figure 2).
For the 1050 women with pN+ disease, allocation to radiotherapy reduced the 1-year recurrence risk
from 26·0% to 5·1%, which is a five-fold reduction (RR 0·20, 95% CI 0·14–0·29). There was a moderate
additional effect over the next few years but little further effect after year 5 (figure 2). When these very
different proportional effects in different periods since treatment were combined, the mean annual
recurrence rate during the whole of the first decade was halved in pN+ disease (RR 0·50, 95% CI 0·41–
0·61). Although the proportional reductions in the mean annual recurrence rate were similar in pN0
and pN+ disease, the absolute 10-year recurrence reduction seemed to be somewhat larger in pN+
disease at 21·2% (95% CI 14·5–27·9, 2p<0·00001, 42·5% vs 63·7%). Radiotherapy also reduced breast
cancer death in pN+ disease (RR 0·79, 95% CI 0·65–0·95, 2p=0·01), with a 15-year absolute reduction
of 8·5% (95% CI 1·8–15·2; 42·8% vs 51·3%).
In both pN0 and pN+ disease, the first recurrence was locoregional for a higher proportion of women
allocated to breast-conserving surgery only than of women allocated to breast-conserving surgery plus
radiotherapy (webappendix p 10).
Analyses of the effects of treatment in various subgroups of women with pN0 disease are much more
likely to identify differences reliably if they are based on recurrence than on mortality, because the
significance level of the effect of radiotherapy is much more extreme for recurrence than for mortality
(2p<0·00001 for recurrence [χ =209·0], 2p=0·005 for breast cancer death [χ =7·8]).
In a series of analyses which focus first on proportional and then on absolute reductions in recurrence,
women were subdivided into different groups to ascertain whether some groups benefit more than
others from radiotherapy. In the first analysis, the proportional effect of radiotherapy on the rate of any
first recurrence in pN0 disease during the first 10 years was estimated for each of several factors
considered separately (figure 3). In most subgroups, radiotherapy roughly halved the annual recurrence
rate (except that among women who had been given lumpectomy the proportional recurrence reduction
was somewhat less extreme in ER-poor disease [2p=0·01, section (d) of figure 3] and somewhat more
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extreme in the low-risk [category C] trials [2p=0·009, section (f) of figure 3]).
Halving a big risk produces a bigger absolute benefit than halving a small risk. In women with pN0
disease, the annual recurrence rate without radiotherapy was strongly correlated with age (inversely),
tumour grade, tumour size, ER status (especially when tamoxifen was used in ER-positive disease), and
extent of surgery (inversely). The absolute recurrence reduction produced by radiotherapy also
depended strongly on these factors (table 2). In the second analysis, the way in which the absolute
reduction in 10-year recurrence risk produced by radiotherapy depended on all the potential
explanatory factors listed in table 2 considered together was modelled. The modelling was carried out
by considering information both for women allocated to radiotherapy and for those allocated to no
radiotherapy (webappendix pp 20–25 shows methodological details).
The absolute recurrence reduction produced by radiotherapy and the absolute recurrence risk
remaining even with radiotherapy varied significantly with age, tumour grade, ER status, and tamoxifen
use, even after adjustment for all other factors (table 2). Tumour size was independently predictive of
absolute recurrence risk although not of the absolute risk reduction.
When the original trials with lumpectomy (category A) and the later trials with lumpectomy in low-risk
women (category C) were compared, there was a substantial difference in the absolute recurrence risk
without radiotherapy and in the absolute reduction in this risk produced by radiotherapy, but these
differences were largely accounted for by the other recorded factors (table 2; webappendix pp 15–17,
19).
Surgery that is more extensive than lumpectomy (as in the category B trials) reduced the absolute
recurrence risk without radiotherapy and reduced the absolute reduction in this risk produced by
radiotherapy. However, because the category B trials did not give tamoxifen, this effect of the extent of
surgery on the absolute effect of radiotherapy was apparent only after adjustment for tamoxifen use
(and the other recorded factors), but not before (table 2; webappendix p 18).
The characteristics that were independently predictive of the absolute risk of recurrence, or of the
absolute risk reduction with radiotherapy, were included in a model to show how 10-year recurrence
risks with and without radiotherapy depended in these trials on age, grade, ER status, tamoxifen (which
was given much more often in the recent category C trials of low-risk patients than in the original
category A trials), and extent of surgery. Figure 4 shows estimates based on this model. Within each
section of the figure, younger women and those with high-grade tumours had substantially larger
absolute recurrence risks without radiotherapy and substantially larger absolute risk reductions with
radiotherapy than did older women and those with low-grade tumours (figure 4). Among women given
lumpectomy but not radiotherapy, for a specific age and grade, the highest risks and largest absolute
reductions with radiotherapy were for women with ER-positive disease not given tamoxifen; however,
even with tamoxifen the additional effects of radiotherapy were substantial for women with high-grade
tumours and younger women with intermediate-grade tumours (figure 4).
Each woman with pN0 disease was assigned a predicted absolute reduction in 10-year recurrence risk
from radiotherapy on the basis of her individual characteristics, the characteristics of the trial that she
was in, and the model-based estimates in figure 4. The absolute reduction in 10-year recurrence risk
was large (≥20%) for 1924 women (56% of women in trial category A, 16% of trial category B, and 9%
of trial category C), intermediate (10–19%) for 3763 women (32%, 74%, and 53% of trial categories A,
B, and C respectively), and lower (<10%) for 1600 women (12%, 10%, and 38% of trial categories A, B,
and C respectively). For these three groups (pN0-lower, pN0-intermediate, and pN0-large), the
observed 10-year recurrence risks with and without radiotherapy, calculated directly from data for
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individual women, were 26.0% versus 50.3% (absolute reduction of 24.3%, 95% CI 19.6–29.0), 12.4%
versus 24.8% (absolute reduction of 12.4%, 9.7–15.1), and 12.0% versus 18.9% (absolute reduction of
6.9%, 2.2–11.6), respectively. The corresponding absolute reductions in 15-year risk of breast cancer
death in the three groups were 7·8% (95% CI 3·1–12·5), 1·1% (–2·0 to 4·2), and 0·1% (–7·5 to 7·7),
respectively (trend in absolute mortality reduction: 2p=0·03; figure 5, webappendix pp 35–37). For all
three groups, the first recurrence was locoregional for a much larger proportion of women allocated to
breast-conserving surgery only than for those allocated to breast-conserving surgery plus radiotherapy
(webappendix pp 38–39). Because only 1050 women had pN+ disease in these trials, the relevance of
prognostic factors and other characteristics could not be explored reliably in this group (webappendix
pp 40–44).
On average, in all the women in these trials, about one breast cancer death was avoided by year 15 for
every four recurrences avoided by year 10 (figure 1). For pN+ disease and for pN0 disease with large
predicted absolute recurrence benefit the observed ratio was slightly larger, whereas for pN0 disease
with intermediate or lower predicted absolute benefit it was somewhat smaller (figure 5). However, the
departure from linearity was not statistically significant (2p=0·11).
Discussion
The overall findings from these trials show that radiotherapy after breast-conserving surgery not only
substantially reduces the risk of recurrence but also moderately reduces the risk of death from breast
cancer. These results suggest that killing microscopic tumour foci in the conserved breast with
radiotherapy reduces the potential for both local recurrence and distant metastasis. Both proportional
and absolute reductions in the annual recurrence rate are largest in the first year but the recurrence
rate continues to be somewhat lower throughout the first decade, whereas the reduction in breast
cancer death rate becomes definite only after the first few years and appears to continue into the
second decade. Non-breast-cancer mortality and the incidence of contralateral and other second
cancers in these and other trials of radiotherapy in early breast cancer will be reported elsewhere, but
there appeared to be little adverse effect on 15-year mortality from the aggregate of all causes other
than breast cancer, so 15-year all-cause mortality was reduced by almost as much as would be expected
from the reduction in breast cancer mortality.
Previous analyses had shown that in pN0 disease young age, large tumour size, and high grade were
each strongly predictive of the risk of locoregional recurrence and of the absolute reduction in that risk
with radiotherapy.5 This report combines the predictive value of these and other factors, such as wider
tamoxifen use in recent trials. Taken together, they account for the fact that the absolute recurrence
reduction with radiotherapy is lower in the more recent postlumpectomy trials (ie, category C trials)
than in the original postlumpectomy trials (ie, category A trials, table 2). However, even for women
with pN0 disease in the recent low-risk trials the predicted absolute 10-year recurrence reduction with
radiotherapy exceeded 10% in most women and exceeded 20% in some women.
Almost a quarter of women with pN0 disease were in trials in which sector resection or
quadrantectomy, rather than lumpectomy, was undertaken and tamoxifen was not trial policy for pN0
disease in any of these trials. Recurrence rates were, however, lower than those for women with similar
characteristics in trials in which lumpectomy was performed (figure 4). This difference accords with the
findings of the one randomised trial of quadrantectomy versus lumpectomy, both with radiotherapy, in
700 women, two-thirds of whom were node negative.25 Most of the trials of radiotherapy after
lumpectomy required negative surgical margins for invasive cancer (although not for ductal carcinoma
in situ). However, pathological techniques have become more sensitive since the women entered these
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trials, and some would probably have been positive with modern techniques. Therefore, whether the
lower recurrence rates recorded in trials of radiotherapy in women given sector resection or
quadrantectomy are simply the result of a reduction in the proportion of women with positive margins,
or whether there is further benefit to be derived from more extensive surgery, is unknown.
The classification of pN0 disease into three groups with large, intermediate, and lower predicted
absolute recurrence benefit from radiotherapy was derived from the recurrence data in these trials. The
classification cannot be validated externally and so should not be overinterpreted. Nevertheless, the size
of the difference in the absolute recurrence reduction between the three groups is striking.
Furthermore, the 15-year reduction in risk of breast cancer death was about as big in pN0 disease with
large predicted absolute recurrence benefit as it was in pN+ disease, whereas in pN0 disease with
intermediate or lower predicted recurrence benefit the mortality reduction was smaller and neither
differed significantly from zero. Therefore the number of breast cancer deaths avoided per recurrence
avoided might be more than one in four in pN+ disease and in pN0 disease with large predicted
absolute recurrence benefit, and less than one in four for women with intermediate or lower predicted
absolute benefit (figure 5). However, the present data do not depart significantly from the one-in-four
relationship.
The main analyses presented are of first recurrence of any type rather than, as previously, locoregional
recurrence as a first event. This difference is partly because it is now clear that radiotherapy after
breast-conserving surgery reduces breast cancer death, so it must also reduce distant recurrence. It is
also because women with higher risk of locoregional recurrence have higher risk of distant recurrence
(ie, the probabilities of locoregional and of distant recurrence are not statistically independent), so valid
estimates of the separate effects of radiotherapy on local and distant recurrence cannot be
obtained.26,27 These issues are more important at 10 years than at 5 years (as presented previously),
because more distant recurrences occur by 10 years than by 5 years. The fact that the proportion of first
recurrences that were locoregional was much lower in irradiated women than in controls does, however,
suggest that the main effect of radiotherapy was to reduce locoregional recurrence, whereas the
reduction of the breast cancer death rate by a sixth suggests that the distant recurrence rate was
reduced by at least as much. No analyses have been undertaken of recurrences after the first, because
they are affected by treatment policies for the first recurrence, and many trials did not record further
recurrences.
Screening, surgery, pathology, radiotherapy, and systemic therapy28,29 have all changed substantially
since most of the women entered these trials, so the absolute recurrence reduction with radiotherapy in
future patients might differ greatly from that recorded in these trials. Moreover, information about
additional risk factors will often be available (eg, HER2, gene expression profile, margin status) and a
radiotherapy boost may be given.30,31 Nevertheless, the finding that radiotherapy roughly halved the
recurrence rate after breast-conserving surgery in a wide range of patients with very different absolute
risks (figure 3) suggests that it might also roughly halve the recurrence rate in future patients given
breast-conserving surgery but who are not comparable with the women included in the trials analysed
here. If so, then in these future patients, a reasonable way to predict the absolute recurrence benefit of
radiotherapy would be to construct contemporary estimates of the absolute risk of first recurrence of
any type and to assume that radiotherapy will approximately halve it.
Correspondence to: EBCTCG Secretariat, Clinical Trial Service Unit (CTSU), Richard Doll Building,
Oxford OX3 7LF, UK bc.overview@ctsu.ox.ac.uk
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Figures and Tables
Figure 1
Effect of radiotherapy (RT) after breast-conserving surgery (BCS) on 10-year risk of any (locoregional or distant) first
recurrence and on 15-year risks of breast cancer death and death from any cause in 10 801 women (67% with
pathologically node-negative disease) in 17 trials
Further details are in webappendix p 5. RR=rate ratio. Rate ratios in this figure include all available years of follow-up.
Figure 2
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 wome...
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Effect of radiotherapy (RT) after breast-conserving surgery (BCS) on 10-year risk of any (locoregional or distant) first
recurrence and on 15-year risk of breast cancer death in women with pathologically verified nodal status
Vertical lines indicate 1 SE above or below the 5, 10, and 15 year percentages. Further details are in webappendix pp 6–7.
pN0=pathologically node-negative. pN+=pathologically node-positive. RR=rate ratio. Rate ratios in this figure include
all available years of follow-up.
Figure 3
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Event rates for any (locoregional or distant) first recurrence (% per year) and recurrence rate ratios for various factors,
considered separately, during years 0–9 in women with pathologically node-negative disease (n=7287)
BCS=breast-conserving surgery. RT=radiotherapy. ER=oestrogen receptor. Categories including unknowns excluded
from tests for trend and heterogeneity. †A trial policy of tamoxifen use gives tamoxifen to both treatment groups if the
disease is ER positive (or ER unknown, here counted with ER positive); additional therapy could be chemotherapy
(usually cyclophosphamide, methotrexate, fluorouracil [CMF]) for both treatment groups, or additional RT (nodal RT or
a boost or both) for those allocated BCS+RT. ‡Definitions of trial categories A, B, and C are in table 1. Further details are
in webappendix p 14.
Figure 4
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 wome...
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Absolute 10-year risks (%) of any (locoregional or distant) first recurrence with and without radiotherapy (RT) following
breast-conserving surgery (BCS) in pathologically node-negative women by patient and trial characteristics, as estimated
by regression modelling of data for 7287 women
Further details are in webappendix pp 27–30 . Results for 5-year risks are in webappendix pp 31–34. Bars show 10-year
risks in women allocated to BCS only, dark sections show 10-year risks in women allocated to BCS plus RT, light
sections show absolute reduction with RT. ER=oestrogen receptor.
Figure 5
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Absolute reduction in 15-year risk of breast cancer death with radiotherapy (RT) after breast-conserving surgery versus
absolute reduction in 10-year risk of any (locoregional or distant) recurrence
Women with pN0 disease are subdivided by the predicted absolute reduction in 10-year risk of any recurrence suggested
by regression modelling (pN0-large ≥20%, pN0-intermediate 10–19%, pN0-lower <10%; further details are in
webappendix pp 35–39). Vertical lines are 95% CIs. Sizes of dark boxes are proportional to amount of information.
Dashed line: one death from breast cancer avoided for every four recurrences avoided. pN0=pathologically node-
negative. pN+=pathologically node-positive.
Table 1
Availability of data from randomised trials of radiotherapy after breast-conserving surgery for invasive
cancer that began before the year 2000
Number
of trials
available
Years
trials
began
Women Deaths Woman-years at risk
Median/woman
Total
(thousands)
Distribution by years
since diagnosis
(thousands)
<5 5–9
10–
14
15–
19
20+
Trial category
(A) Lumpectomy, 1976–
*
†
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original trials6–11
6
86
4398 1982 11·8 52·9 20·3 16·0 10·1 4·8 1·7
(B) Sector resection
or
quadrantectomy12–
15
4
1981–
91
2399 708 12·4 29·4 11·6 10·3 6·0 1·4 0·1
(C) Lumpectomy in
low-risk women16–
22
7
1989–
99
4004 453 6·6 26·9 17·9 7·9 1·1 0·0 0·0
Pathological nodal status
Negative (pN0) .. .. 7287 1801 9·7 73·7 34·0 23·3 11·3 3·9 1·2
Positive (pN+) .. .. 1050 585 10·3 11·8 4·6 3·2 2·2 1·3 0·5
Unknown .. .. 2464 757 8·8 23·6 11·3 7·6 3·7 1·0 0·0
All women 17
1976–
99
10 801 3143 9·5 109·1 49·8 34·1 17·2 6·3 1·7
Only unconfounded trials are considered—ie, trials in which there was no difference between the
treatment groups in the type or extent of surgery or in the use of systemic therapy. Two further eligible
trials,23,24 both category A with a total of 133 women, were identified but data were unavailable.
Details of the 17 available trials are given in webappendix pp 4, 45–47 .
Elsewhere, these trial categories are abbreviated to: (A) Lumpectomy: original; (B) >Lumpectomy; (C)
Lumpectomy: low risk. In category A, 55% were pathologically node negative, 5% were aged 70+ years,
10% had low-grade tumours, 54% had T1 tumours (1–20 mm), 81% had oestrogen-receptor (ER)-
positive disease or unknown status, and 44% were in trials in which tamoxifen was used in both trial
groups. In category B, 81% were pathologically node negative, 10% were aged 70+ years, 9% had low-
grade tumours, 89% had T1 tumours, 86% had ER positive disease or unknown status, and 6% were in
trials in which tamoxifen was used in both trial groups. In category C, 73% were pathologically node
negative, 40% were aged 70+ years, 33% had low-grade tumours, 90% had T1 tumours, 98% had ER
positive disease or unknown status, and 88% were in trials in which tamoxifen was used in both trial
groups.
Table 2
Effect of radiotherapy (RT) after breast-conserving surgery (BCS) on 10-year risk of any (locoregional
or distant) first recurrence in women with pathologically node-negative disease (n=7287), subdivided
by patient and trial characteristics
Number
allocated
BCS+RT/BCS
10-year risk of a locoregional or
distant recurrence (%)
Test for trend/heterogeneity
in absolute reduction
BCS+RT BCS
Absolute reduction
with RT (95% CI)
2p
unadjusted
2p adjusted
(a) Entry age (years) <0·00001 0·0002
<40 189/174 36·1 60·7 24·6 (13·2 to 36·0)
40–49 576/582 20·8 41·4 20·6 (15·1 to 26·1)
50–59 1093/1028 15·0 29·7 14·7 (10·8 to 18·6)
60–69 1138/1167 14·2 28·3 14·1 (10·4 to 17·8)
*
†
*
*
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70+ 679/661 8·8 17·7 8·9 (4·0 to 13·8)
(b) Tumour grade <0·00001 <0·00001
Low 750/757 11·0 22·4 11·4 (6·3 to 16·5)
Intermediate 816/843 16·4 31·6 15·3 (10·4 to 20·2)
High 448/431 28·6 53·3 24·7 (17·6 to 31·8)
Grade unknown 1661/1581 14·7 28·2 13·5 (10·4 to 16·6)
(c) Tumour size 0·02 0·06
T1 (1–20 mm) 2942/2920 12·4 27·5 15·1 (12·7 to 17·5)
T2 (21–50 mm) 513/487 30·7 50·0 19·3 (12·6 to 26·0)
Various/unknown 220/205 24·9 32·6 7·6 (−1·8 to 17·0)
(d) ER status and trial
policy of tamoxifen use
<0·00001 0·003
ER-poor 448/427 28·9 43·8 14·9 (8·0 to 21·8)
ER-positive no
tamoxifen
1686/1626 18·6 36·0 17·4 (14·3 to 20·5)
ER-positive with
tamoxifen
1541/1559 8·7 22·0 13·3 (10·0 to 16·6)
(e) Trial policy of using
additional therapy
0·06 0·45
No 1498/1471 15·8 31·6 15·8 (12·7 to 18·9)
Yes 2127/2085 16·1 31·8 15·6 (12·3 to 18·9)
Some/unknown 50/56 .. .. ..
(f) Trial category
<0·00001 (A vs
C); 0·90 (A+C vs
B)
0·16 (A vs C);
0·00003 (A+C
vs B)
(A) Lumpectomy:
original
1223/1197 27·8 47·9 20·1 (16·0 to 24·2)
(B) >Lumpectomy 986/970 14·3 25·9 11·6 (7·9 to 15·3)
(C) Lumpectomy: low
risk
1466/1445 6·3 19·9 13·6 (9·7 to 17·5)
Total 3675/3612 15·6 31·0 15·4 (13·2 to 17·6)
Information about numbers of events and woman-years is in webappendix p 26. Results for 5-year risks
are in webappendix p 31. ER=oestrogen receptor.
Unadjusted: each factor alone. Adjusted: each factor adjusted for all other factors by means of
regression modelling. Categories including unknowns excluded from test for trend or heterogeneity.
A trial policy of tamoxifen use gives tamoxifen to both treatment groups if the disease is ER positive
(or ER unknown, here counted with ER positive); additional therapy could be chemotherapy (usually
cyclophosphamide, methotrexate, fluorouracil [CMF]) for both treatment groups, or additional RT
(nodal RT or a boost or both) for those allocated BCS+RT.
Definitions of trial categories A, B, and C are in table 1.
†
†
‡
*
†
‡
